Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL528201 | 0.95 | LMNA (0.39) | LMNAL3MBTL1TDP1AKR1B1KDM4E | |
| SCHEMBL999357 | 0.89 | ALDH1A1 (0.35) | LMNAL3MBTL1TDP1USP2 | |
| SCHEMBL2559273 | 0.89 | LMNA (0.39) | LMNAL3MBTL1TDP1AKR1B1PDE4A | |
| SCHEMBL28758113 | 0.86 | USP2 (0.41) | LMNAKDM4EUSP2 | |
| SCHEMBL7556267 | 0.86 | USP2 (0.41) | LMNAKDM4EUSP2 | |
| SCHEMBL15966786 | 0.85 | LMNA (0.39) | LMNAL3MBTL1TDP1AKR1B1KDM4E | |
| SCHEMBL8332379 | 0.85 | LMNA (0.39) | LMNAL3MBTL1TDP1AKR1B1KDM4E | |
| SCHEMBL183848 | 0.84 | LMNA (0.34) | LMNAL3MBTL1TDP1AKR1B1KDM4E | |
| SCHEMBL9476977 | 0.83 | LMNA (0.42) | LMNAL3MBTL1TDP1AKR1B1KDM4E | |
| SCHEMBL27832494 | 0.83 | LMNA (0.42) | LMNAL3MBTL1TDP1AKR1B1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 542 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9186399-B2 | Immune stimulatory oligonucleotide analogs containing modified sugar moieties | AdiutTide Pharmaceuticals GmbH (DE) | 2015-11-17 | — | — | US | claimed |
| EP-2197488-B1 | IMMUNE STIMULATORY OLIGONUCLEOTIDE ANALOGS CONTAINING MODIFIED SUGAR MOIETIES | ADIUTIDE PHARMACEUTICALS GMBH (DE) | 2014-05-07 | — | — | EP | claimed |
| US-20110098456-A1 | IMMUNE STIMULATORY OLIGONUCLEOTIDE ANALOGS CONTAINING MODIFIED SUGAR MOIETIES | ADIUTIDE PHARMACEUTICALS GMBH (DE) | 2011-04-28 | — | — | US | claimed |
| JP-2011500014-A | — | — | 2011-01-06 | — | — | JP | claimed |
| EP-2197488-A1 | IMMUNE STIMULATORY OLIGONUCLEOTIDE ANALOGS CONTAINING MODIFIED SUGAR MOIETIES | Coley Pharmaceuticals GmbH (DE) | 2010-06-23 | — | — | EP | claimed |
| WO-2009047610-A1 | IMMUNE STIMULATORY OLIGONUCLEOTIDE ANALOGS CONTAINING MODIFIED SUGAR MOIETIES | COLEY PHARMACEUTICAL GMBH (DE) | 2009-04-16 | — | — | WO | claimed |
| US-20080050745-A1 | Sugar chain synthesizing agent having beta1,3-N-acetyglucosaminyltransferase activity | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-02-28 | — | — | US | claimed |
| US-20080044425-A1 | POLYPEPTIDES HAVING PHOSPHOLIPASE A2 ACTIVITY | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-02-21 | — | — | US | claimed |
| US-20080015165-A1 | NOVEL POLYPEPTIDE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-01-17 | — | — | US | claimed |
| US-7291491-B2 | Having poly-N-acetyllactosamine sugar chains synthesis-related activity; use in antiinflammation, antiinfection, inhibition of cancer metastasis | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-11-06 | — | — | US | claimed |
| EP-1180525-B1 | TRANSCRIPTIONAL ACTIVATION INHIBITORY PROTEIN | KYOWA HAKKO KOGYO KK (JP) | 2007-01-24 | — | — | EP | claimed |
| US-20040014089-A1 | Polypeptides having phospholipase a2 activity | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2004-01-22 | — | — | US | claimed |
| US-20030166208-A1 | Novel polypeptides | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-09-04 | — | — | US | claimed |
| EP-1329511-A1 | POLYPEPTIDE HAVING PHOSPHOLIPASE A2 ACTIIVTY | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-07-23 | — | — | EP | claimed |
| EP-1197556-A1 | USEFUL POLYPEPTIDE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-04-17 | — | — | EP | claimed |
| EP-1162269-A1 | NOVEL POLYPEPTIDE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-12-12 | — | — | EP | claimed |
| EP-1134230-A1 | NOVEL POLYPEPTIDE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-09-19 | — | — | EP | claimed |
| EP-1108725-A1 | NOVEL POLYPEPTIDE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-06-20 | — | — | EP | claimed |
| EP-1103604-A1 | NOVEL POLYPEPTIDE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-05-30 | — | — | EP | claimed |
| EP-0937775-A2 | Beta 1,3-N-acetylglucosaminyltransferase, DNA encoding it and its use | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1999-08-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098456-A1 | IMMUNE STIMULATORY OLIGONUCLEOTIDE ANALOGS CONTAINING MODIFIED SUGAR MOIETIES | NT5C2, TLR3, TLR9 | LMNA 4781/4885L3MBTL1 4180/4885TDP1 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.